Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of MS, as defined by McDonald et al., criteria # 1-4 (McDonald et al., 2001)~* Between the ages of 18 and 50, inclusive.~* Baseline EDSS score between 0.0 and 5.0, inclusive.~* Have experienced at least one relapse within the 12 months prior to randomization.~* Cranial MRI scan demonstrating lesion(s) consistent with MS.~* Have given written informed consent to participate in the study.~Exclusion Criteria:~* Primary progressive, secondary progressive, or progressive relapsing MS.~* MS relapse has occurred,in the opinion of the investigator, within 50 days prior to randomization and/or the subject has not stabilized from a previous relapse.~* A clinically significant infectious illness within 30 days prior to randomization.~* History of, or abnormal laboratory results indicative of any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal and/or other major disease, that in the opinion of the investigator, would preclude the administration of a recombinant humanized antibody immunomodulating agent for 116 weeks.~* History of severe allergic or anaphylactic reactions or known drug hypersensitivity.~* Unable to perform the Timed 25-foot Walk, 9HPT, and PASAT 3.~* Abnormal blood tests performed at the Screening Visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Natalizumab 300 mg, IV
- Group 2 (Type: PLACEBO_COMPARATOR): Placebo IV infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).